Post a Comment Print Share on Facebook
Featured Terrorismo PSOE Reino Unido Congreso de los Diputados Feijóo

RELEASE: MGI showcases excellence in life sciences at ESCMID Global 2024 (1)

(Information sent by the signatory company).

- 3 reads.

RELEASE: MGI showcases excellence in life sciences at ESCMID Global 2024 (1)

(Information sent by the signatory company)

- MGI Showcases Life Sciences Excellence at ESCMID Global 2024 with Latest DNBSEQ-E25 Sequencer and New Partnership with ABL Diagnostics

BARCELONA, Spain, May 7, 2024 /PRNewswire/ -- MGI Tech (MGI), a company committed to creating core tools and technology to lead life sciences, today introduced the latest addition to its range of sequencers, the DNBSEQ-E25 portable and easy to use, for the European and African market. Additionally, the company showcased its current offering of laboratory sequencing and automation products, including the DNBSEQ-G99 and the entire workflow for the Million Human Microbiome Project (MMHP), at the 34th European Congress of Clinical Microbiology and Diseases. Infectious (ESCMID Global also known as ECCMID 2024). During the event taking place from April 27 to 30 in Barcelona, ​​MGI and ABL Diagnostics (Woippy, France, Euronext: ABLD – ISIN: FR001400AHX6) are pleased to announce their partnership and the compatibility of ABL Diagnostics' DeepChek® assays with MGI DNBSEQ™ platforms.

"MGI once again shows our commitment to supporting scientific and healthcare research and applications in Europe and Africa. At MGI we believe that the power and potential of genomics is limitless," said Dr. Yong Hou, CEO of MGI. Europe and Africa. "By providing our technology, expertise and technical facilities, we hope to enable more companies and institutions to develop content on our DNBSEQ platforms more easily, thereby empowering them in their work to improve the health and well-being of all."

Introducing the portable DNBSEQ-E25 for European and African customers

Answering the question "What if your sequencing capabilities could be mobile?" MGI's flagship product within its E series, DNBSEQ-E25, is a portable and easy-to-use sequencer with daily data throughput of up to 7.5G. Built on the newly designed self-luminous biochemical system, the E25 has upgraded its sequencing system, flow cells and sequencing cartridge, in addition to having built-in bioinformatics. Its ease of setup means it's ready to go in minutes, and a fast response time means PE150 takes just 20 hours from DNB to FASTQ data. DNBSEQ-E25 meets the application needs of infectious diseases, small genome sequencing, small panels and chain verification. The sequencer is now available for European and African customers.

Empower microbiology laboratories through collaboration with ABL Diagnostics

Additionally, at this year's ESCMID Global 2024, MGI announced a technical evaluation of solutions from ABL Diagnostics (ABL), a Euronext-listed company that develops molecular biology assays and microbiology genotyping software. ABL DeepChek® assays have been successfully tested on MGI's DNBSEQ-G400 and DNBSEQ-G99 platforms. Further verification and validation studies of the DeepChek® assays will also be performed on the recently released DNBSEQ-E25.

"This new technical evaluation with MGI will strengthen our presence in microbiological genotyping through the verification of our DeepChek® assays and software on additional next-generation sequencing (NGS) platforms," ​​explained Dimitri González, head of diagnostics at ABL Diagnostics. "Expands access and offering of new types of NGS technology and end-to-end solutions for microbiology laboratories to cover an ever-growing portfolio of infectious disease applications, including, but not limited to, HIV, viral hepatitis, respiratory viruses, tropical infections and tuberculosis.

ABL offers a unique portfolio of assays and downstream analysis software systems for laboratories seeking to implement microbiological genotyping using DNA sequencing, covering a wide range of infectious diseases for clinical diagnostic and research applications.

"MGI is transforming the clinical landscape with our expanded range of instruments designed for the clinical market. Through strategic collaborations with third-party companies in clinical NGS solutions, we are committed to delivering accurate and cost-effective answers to diverse clinical microbiology challenges," he commented. Ludwig Ortner Eurlings, Business Development Director, MGI Europe and Africa. "The debut of the DNBSEQ-E25 marks an important milestone, giving laboratories that handle fewer samples unprecedented access to next-generation sequencing technology. This advancement allows these laboratories to provide faster and more accurate reports to patients , improving diagnostic results and revolutionizing patient care."

MGI's Advanced Life Sciences Product Portfolio Showcase at ESCMID Global 2024

In addition to DNBSEQ-E25, several products from MGI's portfolio of advanced laboratory automation, sequencing platforms and microbiome metagenomics sequencing platform will be on display for customers and partners to explore, including the flagship model DNBSEQ-T7, a sequencer ultra-high performance capable of achieving more than 20,000 30X WGS per year, and DNBSEQ-G99 boasts one of the world's fastest speeds among those with the same performance. Additionally, the company exhibited two automated sample preparation systems, MGISP-960 and MGISP-Smart 8, the MGISTP-7000 high-throughput automated sample transfer processing system, as well as the MGI platform for rapid microbial identification (PFI). with integrated species database for simplified high-throughput genetic sequencing analysis of more than 27,600 microorganisms.

"In line with our global brand campaign 'What if we had a choice?' launched last year, MGI has been empowering scientists and healthcare professionals around the world with our leading technology and innovative products. We are excited to the opportunity to connect with them at ESCMID Global 2024, while introducing MGI's latest DNBSEQ-E25, a portable sequencer designed to perform sequencing and reporting on the go," said Dr. Nicole Neubauer, Marketing Director, MGI Europe and Africa. "In addition, we will showcase our innovative contribution to the MMHP through the patented DNBSEQ™ technology, showcase the rapid pathogen detection workflow on the DNBSEQ-G99, and announce our collaboration with ABL Diagnostics."

MGI welcomes all customers, distributors and partners to exhibitor D23, located in Hall 7 of Fira Barcelona Gran Via, to experience first-hand and learn more about its high-quality sequencers and automation platforms during ESCMID Global 2024.

About MGI

MGI Tech Co. Ltd. (or its subsidiaries, collectively referred to as MGI), headquartered in Shenzhen, is committed to creating core tools and technology to lead life sciences through intelligent innovation. Based on its proprietary technology, MGI focuses on the research and development, production and sales of sequencing instruments, reagents and related products to support research in life sciences, agriculture, precision medicine and healthcare. MGI is a leading producer of high-throughput clinical gene sequencers and its multi-omics platforms include genetic sequencing, medical imaging and laboratory automation. MGI's mission is to develop and advance advanced life sciences tools for the healthcare of the future. For more information, visit the MGI website or connect with us on Twitter, LinkedIn or YouTube.


ABL Diagnostics S.A. (ABLD) is a world-leading international company providing innovative, patented molecular biology assays and end-to-end solutions for molecular detection using polymerase chain reaction (PCR), UltraGene®, and for genotyping. through DNA sequencing, DeepChek®.

ABL Diagnostics, headquartered in Woippy, is a public company listed in compartment B of the Euronext regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products generate recurring revenue and cover one of the largest portfolios of microbiology applications.

ABL Diagnostics markets its entire product line globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiology content in constant expansion.

For more information, visit

Photo - -

View original content: